These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34608329)

  • 1. Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
    Matthews RP; Patel M; Barrett SE; Haspeslagh L; Reynders T; Zhang S; Rottey S; Goodey A; Vargo RC; Grobler JA; Stoch SA; Iwamoto M
    Nat Med; 2021 Oct; 27(10):1712-1717. PubMed ID: 34608329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
    Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
    Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection.
    Matthews RP; Zang X; Barrett SE; Koynov A; Goodey A; Heimbach T; Weissler VL; Leyssens C; Reynders T; Xu Z; Rottey S; Vargo R; Robertson MN; Stoch SA; Iwamoto M
    J Acquir Immune Defic Syndr; 2023 Apr; 92(4):310-316. PubMed ID: 36450129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV.
    Matthews RP; Ankrom W; Friedman E; Jackson Rudd D; Liu Y; Mogg R; Panebianco D; De Lepeleire I; Petkova M; Grobler JA; Stoch SA; Iwamoto M
    Clin Transl Sci; 2021 Sep; 14(5):1935-1944. PubMed ID: 34463432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Pharmacokinetics of Once-Daily Multiple-Dose Administration of Islatravir in Adults Without HIV.
    Matthews RP; Jackson Rudd D; Zhang S; Fillgrove KL; Sterling LM; Grobler JA; Vargo RC; Stoch SA; Iwamoto M
    J Acquir Immune Defic Syndr; 2021 Nov; 88(3):314-321. PubMed ID: 34651606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
    Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; DeJesus E; Olsen Klopfer S; Grandhi A; Eves K; Robertson MN; Correll T; Hwang C; Hanna GJ; Sklar P
    Lancet HIV; 2021 Jun; 8(6):e324-e333. PubMed ID: 34000227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.
    Matthews RP; Jackson Rudd D; Fillgrove KL; Zhang S; Tomek C; Stoch SA; Iwamoto M
    Clin Drug Investig; 2021 Jul; 41(7):629-638. PubMed ID: 34151413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
    Molina JM; Yazdanpanah Y; Afani Saud A; Bettacchi C; Chahin Anania C; Klopfer SO; Grandhi A; Eves K; Hepler D; Robertson MN; Hwang C; Hanna GJ; Correll T
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):68-72. PubMed ID: 35972855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
    Markowitz M; Grobler JA
    Curr Opin HIV AIDS; 2020 Jan; 15(1):27-32. PubMed ID: 31658118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency.
    Matthews RP; Cao Y; Patel M; Weissler VL; Bhattacharyya A; De Lepeleire I; Last S; Rondon JC; Vargo R; Stoch SA; Iwamoto M
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0093122. PubMed ID: 36346229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
    Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection.
    Wonganan P; Limpanasithikul W; Jianmongkol S; Kerr SJ; Ruxrungtham K
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):551-564. PubMed ID: 32508203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates.
    Pons-Faudoa FP; Di Trani N; Capuani S; Campa-Carranza JN; Nehete B; Sharma S; Shelton KA; Bushman LR; Abdelmawla F; Williams M; Roon L; Nerguizian D; Chua CYX; Ittmann MM; Nichols JE; Kimata JT; Anderson PL; Nehete PN; Arduino RC; Grattoni A
    Sci Transl Med; 2023 Jun; 15(702):eadg2887. PubMed ID: 37379369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
    Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
    Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1, open-label study to evaluate the drug interaction between islatravir (MK-8591) and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.
    Ankrom W; Jackson Rudd D; Zhang S; Fillgrove KL; Gravesande KN; Matthews RP; Brimhall D; Stoch SA; Iwamoto MN
    J Int AIDS Soc; 2021 Dec; 24(12):e25858. PubMed ID: 34935295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.
    Zala C; St Clair M; Dudas K; Kim J; Lou Y; White S; Piscitelli S; Dumont E; Pietropaolo K; Zhou XJ; Mayers D
    Antimicrob Agents Chemother; 2012 May; 56(5):2570-5. PubMed ID: 22314532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects.
    Zhou XJ; Pietropaolo K; Damphousse D; Belanger B; Chen J; Sullivan-Bólyai J; Mayers D
    Antimicrob Agents Chemother; 2009 May; 53(5):1739-46. PubMed ID: 19223643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate.
    Rudd DJ; Zhang S; Fillgrove KL; Fox-Bosetti S; Matthews RP; Friedman E; Armas D; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1432-1441. PubMed ID: 34676683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.